Nettelbeck DM - Search Results

1

An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.

Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS. Ulasov IV, et al. Among authors: nettelbeck dm. Int J Oncol. 2007 Nov;31(5):1177-85. Int J Oncol. 2007. PMID: 17912445

2

Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.

Nettelbeck DM, Rivera AA, Balagué C, Alemany R, Curiel DT. Nettelbeck DM, et al. Cancer Res. 2002 Aug 15;62(16):4663-70. Cancer Res. 2002. PMID: 12183423

3

Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA.

Nettelbeck DM, Rivera AA, Kupsch J, Dieckmann D, Douglas JT, Kontermann RE, Alemany R, Curiel DT. Nettelbeck DM, et al. Int J Cancer. 2004 Jan 1;108(1):136-45. doi: 10.1002/ijc.11563. Int J Cancer. 2004. PMID: 14618628

4

Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.

Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT, Nettelbeck DM. Banerjee NS, et al. Among authors: nettelbeck dm. Mol Cancer Ther. 2004 Apr;3(4):437-49. Mol Cancer Ther. 2004. PMID: 15078987

5

Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA 3rd, Yamamoto M, Alvarez RD, Curiel DT. Zhu ZB, et al. Among authors: nettelbeck dm. Gene Ther. 2004 Apr;11(7):645-8. doi: 10.1038/sj.gt.3302089. Gene Ther. 2004. PMID: 15029227

6

Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.

Breidenbach M, Rein DT, Wang M, Nettelbeck DM, Hemminki A, Ulasov I, Rivera AR, Everts M, Alvarez RD, Douglas JT, Curiel DT. Breidenbach M, et al. Among authors: nettelbeck dm. Hum Gene Ther. 2004 May;15(5):509-18. doi: 10.1089/10430340460745829. Hum Gene Ther. 2004. PMID: 15144580

7

Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.

Barker SD, Dmitriev IP, Nettelbeck DM, Liu B, Rivera AA, Alvarez RD, Curiel DT, Hemminki A. Barker SD, et al. Among authors: nettelbeck dm. Gene Ther. 2003 Jul;10(14):1198-204. doi: 10.1038/sj.gt.3301974. Gene Ther. 2003. PMID: 12833129

8

Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.

Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM. Rivera AA, et al. Among authors: nettelbeck dm. Gene Ther. 2004 Dec;11(23):1694-702. doi: 10.1038/sj.gt.3302346. Gene Ther. 2004. PMID: 15496964

9

Evaluation of tumor-specific promoter activities in melanoma.

Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD, Curiel DT, Zhu ZB. Lu B, et al. Among authors: nettelbeck dm. Gene Ther. 2005 Feb;12(4):330-8. doi: 10.1038/sj.gt.3302385. Gene Ther. 2005. PMID: 15696177

10

Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma.

Nettelbeck DM, Rivera AA, Davydova J, Dieckmann D, Yamamoto M, Curiel DT. Nettelbeck DM, et al. Melanoma Res. 2003 Jun;13(3):287-92. doi: 10.1097/00008390-200306000-00010. Melanoma Res. 2003. PMID: 12777984

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters